Ocumetics Technology Corp · TSXV:OTC
Ocumetics Technology — Investor Presentation (March 2026)
22 slides from Ocumetics Technology's investor presentation, March 2026
Slide 1: Accommodating Intraocular Lens Designed To Replicate Natural Vision
Accommodating Intraocular Lens Designed To Replicate Natural Vision ocumetics.com TSXV: OTC.V FSE: 2QB0 OTCQB: OTCFF Investor Pitch Deck Q1 2026 1
Slide 2: Disclaimer
DISCLAIMER Nothing contained in this presentation is or shall be relied upon as a promise, guarantee, representation of or warranty specific or implied as to future performance of Ocumetics Technology Corp. The forward-looking statements contained in this presentation are expressly qualified in thei
Slide 3: Here's the Opportunity
HERE’S THE OPPORTUNITY Breakthrough Innovation Strong Leadership ● Successful First-In-Human (FIH) implants - August 2025 ● CEO Dean Burns: ex-Alcon Vision ($750M BU, 15 FDA ● Designed for rapid, dynamic focus approvals, $6B in product launches) ● Multiple global patents & patents pending ● Backed b
Slide 4: The Problem: Sight loss with Age
THE PROBLEM About Sight loss with Age 83% Adults aged 45 and older in The eye deteriorates as we age, developing the following conditions: the U.S. experience ● Presbyopia (age 45+): Loss of accommodation – inability to focus presbyopia ● Cataracts (age 65+): Cloudy, inflexible natural – blindness i
Slide 5: The Solution
THE SOLUTION No Silicone Oil Chamber Biometric Vision Restoration ● Designed to avoid fragile silicone oil ● Designed to restore biometric vision chambers used in competitor implants, ● Designed to replicate natural eye biomechanics using preventing leakage, clouding, and long- shape-changing lens t
Slide 6: What Is the Natural Lens Biokinetics?
WHAT IS THE NATURAL LENS BIOKINETICS? Instant Dynamic Focusing ● Shifts focus from near to far in under one second, ensuring seamless clarity for reading, driving, or distance viewing Tense Relaxed Non-Accommodated Accommodated Tense muscles & attachments Relaxed muscles & attachments What is Accomm
Slide 7: Strong Global IP
Strong Global IP UNITED STATES FDA • The Food and Drug Administration (FDA) Centre for Devices and Radiological Heal th (CDRH) is responsible for regulatory firms wh o manufacture, repackage and/or relabel medical devices. • IOLs are class III medical devices tha t require premarket approval. • Manu
Slide 8: Ocumetics Achieves Historic First: Accommodating IOL Implanted in Human Patients
August 18,2025 Ocumetics Achieves Historic First: Accommodating Intraocular Lens Successfully Implanted In Human Patients How was this successful? - Achieved biocompatible success (animal safety) - Successfully manufactured the appropriate dioptor lens for the study - Successfully received ethics co
Slide 9: Successfully Implanted – August 15, 2025
SUCCESSFULLY IMPLANTED – AUGUST 15, 2025 Four Hours Post Surgery First two patients successfully received the Ocumetics Lens 69 79 yrs old yrs old First Human Patients Tense Relaxed Close up of eye during surgery with outline of the Ocumetics Lens Accommodating Intraocular Lens Designed To Replicate
Slide 10: Successfully Implanted – Actual Vision Correction Demonstrated
SUCCESSFULLY IMPLANTED – AUGUST 15, 2025 ACTUAL VISION CORRECTION DEMONSTRATED IN ONE PATIENT BEFORE AFTER Accommodating Intraocular Lens Designed To Replicate Natural Vision 10
Slide 11: What Do the Experts Say?
What do the experts say? Dr. Ron Krueger “In my opinion, as a cataract and refractive surgeon with more than 30 years of experience, and as a Professor and Chairman of an academic department of Ophthalmology, the recently reported first-in-world outcomes of the Ocumetics Lens in cataract surgery hig
Slide 12: Accommodating Intraocular Lens (IOL) Competition
ACCOMMODATING INTRAOCULAR LENS (IOL) COMPETITION Atia ● Shape-changing, fluid filled based with fixed-power anterior optic for target refraction ● FIH clinical data 2023 ● FDA multi-phase study (2026–28) Alcon Fluid Vision ● Silicone oil-filled haptics ● Accommodative effort moves fluid from haptics
Slide 13: IOL Technology Analysis
IOL TECHNOLOGY ANALYSIS Technology Distance Intermediate Near Side Effects Monofocal No Extended Depth of No Focus Bifocal Yes* Trifocal Yes* Ocumetic Lens No * Side effects = Halos, ghosting, starbursts and light scatter Accommodating Intraocular Lens Designed To Replicate Natural Vision 13
Slide 14: Market Analysis
MARKET ANALYSIS Ocumetics’ strategy is to initially enter the $1.2Bn, 65+ Cataract surgery segment $4.5B Ocumetics has a pipeline of lenses designed to address the larger markets Total Intraocular Lens Market Premium IOL (45+Only) Segment $1.7B Premium IOL (65+Only) Segment $1.2B Accommodating Intra
Slide 15: Procedure Analysis
PROCEDURE ANALYSIS US 3.5 – 4.0M Procedures Annually US PROCEDURES/YR Most recent ophthalmology and cataract surgery statistics put the U.S. volume at ~3.7–4.1 million cataract surgeries per year. The figure matches industry sources (e.g., American Academy of Ophthalmology, Market Scope). 3.5-4M 3 –
Slide 16: Acquisitions by Majors
ACQUISITIONS BY MAJORS Of Less Advanced Ocular Technologies Development Stage at Acquisition Company Technology Focus(2) Acquirer Year Status Acquisition Value (USD)(1) + up to $135M $285M milestones PowerVision Silicone oil-based AIOL Preclinical Alcon 2019 upfront (2) FIH Clinical trials paused Sy
Slide 17: Current Clinical Milestones
CURRENT CLINICAL MILESTONES First-In-Human up to 30 Patient Study Milestone Estimates FIH Group 2 Submit FDA (6 months) Regulatory Documents FIH Group 1 FIH Group 3 (6 months) (6 months) Q2 Q4 Q3/Q4 2026 Q3 2026 2025 2026 Focus Safety, Distance, and Focus Near Focus Safety, Safety and Distance Dista
Slide 18: Corporate Structure
CORPORATE STRUCTURE Shares Outstanding 129M 3.2M ($0.125: April and August 2026) Options 1.6M ($0.32: June 2028) 5.5M 732k ($1.16: Oct 2030) Restricted Share Units Subject to Performance Milestones 5M 1.8M ($0.50: July 2027) Warrants 2.0M ($0.75: December 2028) 12.9M 9.1M ($0.58: June 2027) Converti
Slide 19: Dean Burns
DEAN BURNS Dean Burns CEO, President & Director Former Senior Director at Alcon Vision, managing a $750M business unit across devices, disposables, intraocular lenses (IOLs), and pharmaceuticals. Successfully led 15 FDA approvals and 15 product launches with a combined $6B commercial value, while pa
Slide 20: Management & Directors
MANAGEMENT & DIRECTORS Roger Jewett CA, CPA Dr. Garth Webb Raymond Marks CFO & Director Founder, CSO & Director Director With over 25 years of experience leading public and He is the Founder of Ocumetics and sole inventor Raymond Marks has over 50 years of experience in as an private companies, he h
Slide 21: Management & Directors
MANAGEMENT & DIRECTORS Dr. James B McRoberts,O.D. Michael Edwards Robert Quinn Director Director Director With over 40 years of experience in optometry, He is a Director at Pinnacle Wealth Brokers, one of He is an independent businessman with extensive board, including private practice in British Co
Slide 22: Contact Information
CONTACT INFORMATION Contact: Website: Address: Dave Burwell ocumetics.com 639 5 Ave SW #1250 Director, Investor Relations Calgary, AB 403-410-7907 T2P 0M9 dave.burwell@ocumetics.com Canada TSXV: OTC.V FSE: 2QB0 OTCQB: OTCFF Accommodating Intraocular Lens Designed To Replicate Natural Vision 22
Ocumetics Technology — Investor Presentation (March 2026) on 6ix